GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cocrystal Pharma Inc (NAS:COCP) » Definitions » Interest Coverage

Cocrystal Pharma (Cocrystal Pharma) Interest Coverage : N/A (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Cocrystal Pharma Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Cocrystal Pharma's Operating Income for the three months ended in Dec. 2023 was $-5.67 Mil. Cocrystal Pharma's Interest Expense for the three months ended in Dec. 2023 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Cocrystal Pharma Inc has enough cash to cover all of its debt. Its financial situation is stable.

The historical rank and industry rank for Cocrystal Pharma's Interest Coverage or its related term are showing as below:


COCP's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 137.02
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Cocrystal Pharma Interest Coverage Historical Data

The historical data trend for Cocrystal Pharma's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Cocrystal Pharma Interest Coverage Chart

Cocrystal Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - N/A

Cocrystal Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A No Debt N/A

Competitive Comparison of Cocrystal Pharma's Interest Coverage

For the Biotechnology subindustry, Cocrystal Pharma's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cocrystal Pharma's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cocrystal Pharma's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Cocrystal Pharma's Interest Coverage falls into.



Cocrystal Pharma Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cocrystal Pharma's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Cocrystal Pharma's Interest Expense was $0.00 Mil. Its Operating Income was $-21.16 Mil. And its Long-Term Debt & Capital Lease Obligation was $1.61 Mil.

GuruFocus does not calculate Cocrystal Pharma's interest coverage with the available data.

Cocrystal Pharma's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Cocrystal Pharma's Interest Expense was $0.00 Mil. Its Operating Income was $-5.67 Mil. And its Long-Term Debt & Capital Lease Obligation was $1.61 Mil.

GuruFocus does not calculate Cocrystal Pharma's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Cocrystal Pharma  (NAS:COCP) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Cocrystal Pharma Interest Coverage Related Terms

Thank you for viewing the detailed overview of Cocrystal Pharma's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Cocrystal Pharma (Cocrystal Pharma) Business Description

Traded in Other Exchanges
Address
19805 North Creek Parkway, Bothell, WA, USA, 98011
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
Executives
Fred Hassan director C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON FL 33487
Frost Phillip Md Et Al director, 10 percent owner 4400 BISCAYNE BLVD, MIAMI FL 33137-3227
Pfenniger Richard C Jr director 4400 BISCAYNE BLVD., MIAMI FL 33137
Raymond F Schinazi director, 10 percent owner 1860 MONTREAL ROAD, TUCKER GA 30084
Anthony J Japour director 19805 N. CREEK PARKWAY, BOTHELL WA 98011
Todd R. Brady director 19805 N. CREEK PARKWAY, BOTHELL WA 98011
James Joseph Martin officer: Interim CFO 4400 BISCAYNE BLVD, SUITE # 670, MIAMI FL 33157
Curtis Dale officer: INTERIM CFO 1860 MONTREAL ROAD, TUCKER GA 30084
Douglas L Mayers officer: CHIEF MEDICAL OFFICER C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02139
Walt Addison Linscott officer: GENERAL COUNSEL AND SECRETARY 1860 MONTREAL ROAD, TUCKER GA 30084
Jeffrey A Meckler director 740 BROADWAY, 9TH FLOOR, NEW YORK NY 10003
David S Block director
Hsiao Jane Ph D director 4400 BISCAYNE BLVD, MIAMI FL 33137
Steven D Rubin director OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Roger D. Kornberg director 345 WALSH ROAD, ATHERTON CA 94027

Cocrystal Pharma (Cocrystal Pharma) Headlines

From GuruFocus

Cocrystal Pharma Announces Participation in Virtual Investor Events

By Stock market mentor Stock market mentor 01-26-2023